Phelan Piehota, DO
Ophthalmology · Ladson, SCNPI 1548534381
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,564 of the $10,237 with a category attached, or 83.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.
Across 344 payments — averaging $29.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2K
- AbbVie$1K
- Amgen$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Alcon$930
- Mallinckrodt Hospital Products Inc.$723
- plus $4K from 29 others
What the payments were for
- Consulting fees$1,57515%
- Food & beverage$8,56484%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $1,575 |
| AbbVie(2 entities) | 45 | $1,079 |
| Amgen(2 entities) | 45 | $1,069 |
| Johnson & Johnson Surgical Vision, Inc. | 21 | $1,008 |
| Alcon | 43 | $930 |
| Mallinckrodt Hospital Products Inc. | 33 | $723 |
| NEW World Medical,inc. | 10 | $680 |
| Tarsus Pharmaceuticals, Inc. | 16 | $409 |
| Sun Pharmaceutical Industries Inc. | 22 | $402 |
| Kala Pharmaceuticals, Inc. | 20 | $338 |
| Bausch & Lomb Americas Inc. | 12 | $313 |
| Biotissue Holdings Inc. | 6 | $311 |
| Novartis | 16 | $300 |
| Rayner Intraocular Lenses Limited | 10 | $199 |
| Glaukos Corporation | 6 | $135 |
| Harrow Eye, LLC | 6 | $115 |
| Dompe US, Inc. | 4 | $81 |
| Aerie Pharmaceuticals, Inc. | 4 | $74 |
| Optos, Inc. | 1 | $69 |
| Ocular Therapeutix, Inc. | 3 | $56 |
| Rxsight Inc | 3 | $55 |
| Oyster Point Pharma, Inc. | 2 | $48 |
| Omeros Corporation | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Akorn, Inc. | 1 | $24 |
| Lensar, Inc. | 1 | $20 |
| Thea Pharma Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Ivantis, Inc | 1 | $15 |
| Sight Sciences, Inc. | 1 | $14 |
| Carl Zeiss Meditec USA, Inc. | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$1,575
- TEPEZZA$481
- Tecnis IOL$392
- Kahook Dual Blade$252
- Clearpath$252
- Ahmed Glaucoma Valve$252
- Streamline$252
- Via360$128
- DURYSTA$127
- Tecnis Multifocal Family of 1-piece IOLS$125
- OZURDEX$120
- VUITY$120
- CATALYS SYSTEM$117
- Clareon$114
- Tecnis Symfony IOL$107
How this compares
$10,237 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 86 | $112,773 |
| XiidraLifitegrast | 32 | $47,893 |
| XdemvyLotilaner | 14 | $25,866 |
| CombiganBrimonidine Tartrate/Timolol | 40 | $19,417 |
| LumiganBimatoprost | 24 | $16,171 |
| Cyclosporine | 39 | $14,928 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $12,467 |
| RhopressaNetarsudil Mesylate | 13 | $4,831 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $4,324 |
| Prednisolone Acetate | 70 | $2,524 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 169 | $1,824 |
| Latanoprost | 187 | $1,607 |
| Ketorolac Tromethamine | 36 | $916 |
| Timolol Maleate | 108 | $903 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $1,079 | $148,361150 claims |
| Bausch & Lomb Americas Inc.Xiidra | $313 | $47,89332 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $409 | $25,86614 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $74 | $17,29839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Ladson
- David VromanLadson$61K
- Kristiana NeffLadson$23K
- Millin BudevLadson$16K
- John ThompsonLadson$13K
- Rachel EllynLadson$11K
- Michelle YingLadson$7K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.